The prevalence of attention-deficit/hyperactivity disorder (ADHD) identified in an outpatient sample of 492 adults seeking mental health treatment was nearly 10 times higher than the prevalence identified in epidemiological studies, according to a poster presented at the recent 2018 Annual Meeting of The American Professional Society of ADHD and Related Disorders.
The prevalence of attention-deficit/hyperactivity disorder (ADHD) identified in an outpatient sample of 492 adults seeking mental health treatment was nearly 10 times higher than the prevalence identified in epidemiological studies, according to a poster presented at the recent 2018 Annual Meeting of The American Professional Society of ADHD and Related Disorders (APSARD).
The authors, from the Penn State College of Medicine, wrote that the goal of the study was to examine the prevalence of ADHD in an adult outpatient setting and to examine the unique association between ADHD symptoms and functional impairment, controlling for co-occurring mental health concerns.
Despite the fact that approximately 4% of US adults are diagnosed with ADHD, there have been few studies of its prevalence and associated illness in clinical samples of adults seeking outpatient psychiatric care.
The sample was nearly 70% female and the mean age was 40; patients were starting mental health services. Researchers collected information on the total number of ADHD symptoms using the Adult ADHD Self-Report Scale (ASRS); the average score on the WHO Disability Assessment Schedule 2.0 for overall impairment; and co-occurring psychopathology on the DSM-5 Self-rated Level Cross-Cutting Symptom Measure.
Co-occurring psychopathology screening items included: depression, suicidality, mania, anxiety, sleep problems, and substance abuse. These scores were used as covariates.
ADHD symptoms contributed to the functional impairment of patients with a wide range of psychiatric symptoms. Age, depression, anxiety, substance abuse, mania, and sleep difficulty also explained a significant portion of variance in impairment, while gender and suicidality did not.
Using DSM-IV symptom count criteria (ie, 6+ inattention and/or hyperactivity/impulsivity symptoms), 40.85% of the sample met criteria for ADHD (110 inattentive, 24 hyperactive/impulsive, and 67 combined type). A total of 51.83% met DSM-5 symptom count criteria (125 inattentive presentation, 30 hyperactive/impulsive presentation, and 100 combined presentation).
The authors wrote that the results stress the need for further assessment of ADHD, including diagnostic interview and collateral rating, in standard mental health care for adults.
Reference
Babinski DE, Waxmonsky JG, Bixler EO, et al. Screening for ADHD and impairment in a general outpatient psychiatric sample of adults. Poster presented at the 2018 Annual Meeting of The American Professional Society of ADHD and Related Disorders; Washington, DC; January 12-14, 2018. Poster 32.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More